


Docket Number: 037003-0276658

Client Reference: 1999-30-0466CP2



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

NABIL HANNA et al.

Group Art Unit: 1644

Application No.: 09/772,938

Examiner: Phillip Gambel

Filed: January 31, 2001

Confirmation No.: 9882

For: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED APPLICATIONS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed with a Request for Continued Examination. No certification or fee is required.

Respectfully Submitted,

Thomas A. Cawley, Jr., Ph.D,  
Registration Number 40944

TAC/JBM:ntb  
Date: October 8, 2003  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102

☐